7:45 am Chair’s Opening Remarks

Highlighting Promising Novel Targets & Therapies to Modulate the Myeloid Compartment

8:00 am KEYNOTE PRESENTATION: Engineering Myeloid Cells to Find, Recognize, & Penetrate Tumors, & Prime the Immune System to Enforce an Anti-Tumor Response

  • Judith Varner Professor of Pathology, University of California San Diego


• Discussing why myeloid cells are an attractive therapeutic target in solid and hematological conditions, with their frequent migration into solid tumors, bone marrow, and inflammation sites

• Directing phagocytic properties of myeloid cells to recognize and engulf cancer cells

• Bridging innate and adaptive immunity to elicit a comprehensive anti-tumor response

• Empowering myeloid cells to produce anti-tumor agenda and modify the tumor microenvironment

9:00 am Developing Engineered CAR-Macrophages for Solid Tumor Immunotherapy


• Mapping the localization and migration of CAR-macrophages to determine concentrations at the tumor site

• Investigating the plasticity of engineered Macrophages and the persistence of cells and efficacy in vivo and drawing parallels with first in-patient data

• Sharing safety data and pharmacodynamic profiles of engineered macrophages

• Reflecting on interactions with regulators in bringing myeloid-derived cell therapies into the clinic with safety and efficacy data

9:30 am Sharing Concept-to-Clinic Development of Myeloid Checkpoint Inhibitors


  • Reprogramming myeloid cells with myeloid checkpoint inhibitor antibodies to diminish inhibitory signals and halt the immune suppressive activity of myeloid cells in solid tumors
  • Outlining the impact of checkpoint inhibition on multiple myeloid cell subsets, including dendritic cells, tumor-associated macrophages, monocytes, and neutrophils
  • Demonstrating the specific and non-redundant role of LILRB myeloid checkpoints

10:00 am Morning Refreshments & Networking

Sharing Preclinical Workflows to Accelerate Novel Myeloid-Directed Therapies Into the Clinic

11:00 am Moving Single-cell DNA Sequencing into Solid Tumor Research

11:30 am Sharing Preclinical Studies of Myeloid Repolarization to & Recruiting Adaptive Immunity & Orchestrate Comprehensive Anti- Tumor Mechanisms


• Discussing which platforms and techniques bear translational relevance to the tumor myeloid microenvironment, and strategies to recapitulate in vivo dynamics

• Studying chemotaxis and migration of myeloid cells and how this correlates with repolarization

• Examining the cytokines and chemokines involved in, and modulated by, myeloid biology and how they orchestrate myeloid cell repolarization and migration

• Enhancing myeloid cell response to recruit additional T cells, increase antigen presentation, to bridge the innate and adaptive immune systems, and modulate vasculature to drive T cell infiltration

• Outlining therapeutic strategies to prevent further repolarization and transformation of macrophages

12:00 pm Addressing Human Myeloid Compartment in a Preclinical Mouse Model Featuring Human Immune System

  • Kader Thiam SVP, Discovery, Preclinical Models & Services, genoway


• BRGSF-HIS mice: Immunodeficient mouse model featuring human immune system (HIS) with functional lymphoid and myeloid compartments

• Examining myeloid and lymphoid cell recruitment in the TME

• Assessing immune-modulation induced by biologics in BRGSF-HIS model, which displays a wide therapeutic window

12:30 pm Sharing the Discovery of Multifunctional Anti Singlec15 mAb to Reverse Immune Suppression and Synergize with CIC Treatment


• Outlining the Siglec15 target biology validation

• Discussing EPB-001 discovery with mRNADisTM technology

• Examining the in vitro and in vivo mechanism and efficacy studies of EPB-001

• Discussing next steps in the development plan

1:00 pm Lunch & Networking

Demystifying Cell Types Beyond Macrophages & Their Role in Tumor Progression & Therapeutic Potential

2:00 pm Engaging FLT3 to Promote Dendritic Cell Expansion & Recruit Adaptive Immunity Anti-Tumor Responses


• Investigating mechanisms of action in dendritic cell anti-tumor responses

• Bridging the gap between adaptive and innate immune responses with dendritic cell

• Discussing the importance of cross-presentation by dendritic cells, and strategies to foster activity through therapy

2:30 pm Panel Discussion: Gauging the Translational Relevance of Current Preclinical Platforms & Setting Industry Gold Standards

  • Kehao Zhao CSO, Elpis Biopharmaceuticals
  • Kareem Azab Associate Professor, Cancer Biology Division, Department of Radiation Oncology, Washington University St. Louis
  • Jasper Mullenders Director Translational Research, Scenic Biotech


• Discussing the use of multiplexed immunohistochemistry to understand tissue and tumor dynamics in the myeloid compartment

• Considering how to maintain myeloid cells ex vivo with in vivo phenotypes to minimize artefacts in assays

• Proposing a back-translation workflow to learn from mechanisms and feed them into drug design, as well as contrasting patent response vs. in vitro findings

3:29 pm **TAM Depletion vs Reprogramming: Why Both Have Merit


• Sharing lessons learned from depleting macrophages in cancer patients

• Providing ipdates on clinical development of emactuzumab, aCSF1R blocking antibody that depletes tumor-associated macrophages (TAM)

• Harnessing TAM heterogeneity to design novel TAM reprogramming agents

**Unfortunately Carola is unable to join us in person, but her slides will be made available post-event

3:30 pm Afternoon Poster Session & Networking

Driving Efficacy Through Combination Therapy to Unlock Better Clinical Outcomes

4:00 pm Panel Discussion: Combination vs. Single Agent Therapy: What Does the Future Look Like?


• Discussing the advantages and challenges of single agent vs. combination of myeloid therapies with existing
treatment regimens
• Highlighting areas of need in combinations based on mechanistic understanding and medical need
• Considering the challenges of multi-agent therapy with toxicity and demonstrating added benefit of
combination therapy to regulators

4:30 pm Clearing Out the Myeloid Compartment to Drive Effector Cell Function, Demonstrating Clinical Mechanisms, & Benefit of Combination Therapies Targeting the CCL2 & CXCL12 Pathways


• Outlining resistance mechanisms to therapies such as checkpoints and T cell therapies, and demonstrating tumor regression in resistant patients through combination therapy

• Deciphering the mechanisms through which myeloid cells drive resistance to other therapies, and showing restored anti-tumor function through blocking myeloid recruitment

• Deploying myeloid therapies to overcome resistance in synergy with immunotherapy to enhance efficacy whilst balancing toxicity vs. efficacy of combination therapies

5:00 pm Sharing Preclinical Findings of Myeloid-Targeting Therapies in Combination with Immunotherapy to Demonstrate Added Therapeutic Benefit


• Stating the goal of deploying myeloid-directed therapy in combination with immunotherapy and sharing mechanistic rationale

• Presenting preclinical and translational findings of combination therapies

• Separating the single agent effect of tumor myeloid therapies to demonstrate added benefit in combination

• Discussing how to combine myeloid therapies with experimental therapies earlier in development, and how to time doses, with myeloid therapies to prime the microenvironment vs. co-administration

5:30 pm Chair’s Closing Remarks

5:45 pm End of Day One